New Busulfan Therapy Findings from Lineberger Comprehensive Cancer Center Discussed (Utilization of a Population Pharmacokinetic Model To Improve a Busulfan Test-dose Strategy In Allogeneic Hematopoietic Cell Transplant Recipients).

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Abstract:
      In this study, PK data were retrospectively collected from busulfan drug monitoring records from adult allo-HCT recipients who received once-daily intravenous busulfan at the University of North Carolina Medical Center (UNCMC). Keywords: Chapel Hill; State:North Carolina; United States; North and Central America; Alkanesulfonic Acids; Alkylating Agents; Antineoplastics; Busulfan; Busulfan Therapy; Butylene Glycols; Drugs and Therapies; Health and Medicine; Hematology; Hematopoietic; Mesylates; Pharmaceuticals; Pharmacokinetics; Pharmacology; Sulfur Acids EN Chapel Hill State:North Carolina United States North and Central America Alkanesulfonic Acids Alkylating Agents Antineoplastics Busulfan Busulfan Therapy Butylene Glycols Drugs and Therapies Health and Medicine Hematology Hematopoietic Mesylates Pharmaceuticals Pharmacokinetics Pharmacology Sulfur Acids 860 860 1 07/10/23 20230713 NES 230713 2023 JUL 14 (NewsRx) -- By a News Reporter-Staff News Editor at Hematology Week -- New research on Drugs and Therapies - Busulfan Therapy is the subject of a report. [Extracted from the article]
    • Abstract:
      Copyright of Hematology Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)